Abstract
Inhibition of platelet P2Y12 ADP (adenosin diphosphate) receptors is a well-established therapeutic strategy in reducing thrombotic complications in both acute and chronic cardiovascular events and instrumental procedures in the arterial system. The administration of the gold standard, clopidogrel, is associated with bout 30% resistance to therapy as a result of bioactivation enzyme polymorphysms.
For these reasons, novel ADP receptor inhibitors were introduced.